The new policy applies to all health plans across Pennsylvania, New York, West Virginia and Delaware, “removing financial barriers for essential breast cancer diagnostics.”
AI is an icy landslide sweeping through healthcare. Even surgeons must choose between two stark options: Ride the crest of the powder cloud now or dig yourselves out of a deep runout zone later.
The U.S. Department of Justice alleges that 52-year-old Ritesh Kalra, MD, wrote 50 prescriptions a day for addictive painkillers and billed New Jersey Medicaid for patient visits that never occurred. The alleged incidents occurred between 2019 and 2025.
Numerous “alternative funding programs” are named as defendants in what is a larger challenge of the right of these third-party organizations to import drugs from overseas, bypassing FDA regulations.
Philadelphia-based Jefferson Health has accused the three biggest PBMs—Caremark, Express Scripts and Optum Rx—of a de facto collusion scheme involving the primary makers of insulin, Eli Lilly, Novo Nordisk and Sanofi. The lawsuit alleges rebates offered by the manufacturers unfairly burden self-insured and public health plans, like the one the health system uses for its employees.
A vulnerable heart patient required TAVR, but he faced an extremely high risk of coronary obstruction. Leaflet modification and snorkel stenting were not possible, so the group turned to a brand new treatment option: the VECTOR procedure.
The Scottsdale, Arizona-based radiology practice issued a notice to impacted parties on March 28 after reports of the hack first started surfacing in mid-February.
Michael J. Reardon, MD, shared the highly anticipated data with a large audience at ACC.25 in Chicago. Overall, he said, these five-year findings suggest TAVR with a supra-annular, self-expanding valve is a safe and effective alternative to SAVR.
There are at least 65 consolidated cases pending in federal courts that stem from the 2024 data breach on the claims processor's network. A judge in Minnesota has asked that the lawsuits be coordinated and consolidated as much as possible.
The new policy applies to all health plans across Pennsylvania, New York, West Virginia and Delaware, “removing financial barriers for essential breast cancer diagnostics.”
